Home > References > Treatment Recommendations > Neonates/Paediatric & Adult Patients > Febrile Neutropenia

Febrile Neutropenia

  1. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al.  Ciprofloxacin vs an aminoglycoside in combination with a ß-lactam for the treatment of febrile neutropenia:  a meta-analysis of randomized trials.  Mayo Clin Proc 2005;80:1146-56.
  2. Bodey GP.  Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993;17:S378-84.
  3. Bodey GP.  Evolution of antibiotic therapy for infection in neutropenic patients: studies at M.D. Anderson Hospital. Rev Infect Dis 1989;11:S1582-90.
  4. Bohme A, Shah PM, Stille W, et al.  Piperacillin-tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenia patients:  a prospective randomized pilot study.  Eur J Med Res 1998;3:324-30.
  5. Bow EJ.  Management of the febrile neutropenic cancer patient:  lessons from 40 years of study.  Clin Microbiol Infect 2005;11(suppl 5):24-9.
  6. Bustamante CI.  Initial empiric therapy for fever in neutropenia. Recent Results in Cancer Research 1993;132:45-56.
  7. Cooper MR, Durand CR, Beaulac MT, et al.  Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.  Ann Pharmacother 2011;45:1094-102.
  8. Del Favero A, Menichetti F, Martino P, et al.  A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.  Clin Infect Dis 2001;33:1295-301.
  9. EORTC International Antimicrobial Therapy Cooperative Group.  Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
  10. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
  11. Freifeld AG, Bow EJ, Sepkowitz KA, et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:  2010 update by the Infectious Diseases Society of America.  Clin Infect Dis 2011;52:e56-93.
  12. Freifeld AG, Walsh T, Marshall D, et al.  Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncology 1995;13:165-76.
  13. Giamarellou H, Bassaris HP, Petrikkos G, et al.  Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.  Antimicrob Agents Chemother 2000;44:3264-71.
  14. Giamarellou H.  Empiric therapy for infections in the febrile, neutropenic, compromised host. Med Clin North Am 1995;79:559-80.
  15. Glasmacher A, Hahn C, Molitor E, et al.  A randomized comparison of piperacillin-tazobactam vs. ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies.  Interscience Conference on Antimicrobial Agents and Chemotherapy 1999; Abstract 1090.
  16. Glasmacher A, vonLilienfeld-Toal M, Schultz S, et al.  An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients.  Clin Micro Infection 2005;11(suppl 5):17-23.
  17. Hathorn JW, Rubin M, Pizzo PA.  Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother 1987;31:971-7.
  18. Hess U, Bohme C, Rey K, et al.  Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.  Support Care Cancer 1998;6:402-9.
  19. Hughes WT, Armstron D, Bodey GP, et al.  Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
  20. Hughes WT, Armstrong D, Bodey GP, et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
  21. Hughes WT, Armstrong D, Bodey GP, et al.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.  Clin Infect Dis 2002;34:730-51.
  22. Kern WV.  Risk assessment and treatment of low-risk patients with febrile neutropenia.  Clin Infect Dis 2006;42:533-40.
  23. Kinsey SE, Machin SJ, Goldstone AH.  Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. J Hosp Infect 1990;15:49-53.
  24. Liles WC, Dale DC.  Current approach to the management of neutropenia. J Intensive Care Med 1995;10:283-93.
  25. Link H, Maschmeyer G, Meyer P, et al.  Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 1994;69:231-43.
  26. Lortholary O, Lefort A, Tod M, et al.  Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia.  Lancet Infect Dis 2008;8:612-20.
  27. Martino P, et al.  Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992;49:49-52.
  28. Mavros MN, Polyzos KA, Rafailidis PI, et al.  Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia:  a systematic review and meta-analysis.  J Antimicrob Chemother 2011;66:251-9.
  29. Palazzi DL.  The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia.  Pediatr Infect Dis J 2011;30:887-90.
  30. Paul M, Borok S, Fraser A, et al.  Empirical antibiotics against Gram-positive infections for febrile neutropenia:  systematic review and meta-analysis of randomized controlled trials.  J Antimicrob Chemother 2005;55:436-44.
  31. Paul M, Soares-Weiser K, Leibovici L.  ß lactam monotherapy versus ß lactam-aminoglycoside combination therapy for fever with neutropenia:  systematic review and meta-analysis.  BMJ 2003;326:1111-9.
  32. Paul M, Yahav D, Fraser A, et al.  Empirical antibiotic monotherapy for febrile neutropenia:  systematic review and meta-analysis of randomized controlled trials.  J Antimicrob Chemother 2006;57:176-89.
  33. Peacock Jr. JE, Herrington DA, Wade JC, et al.  Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients.  A randomized, double-blind trial.  Ann Intern Med 2002;137:77-86.
  34. Pizzo PA.  Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute. J Hosp Infect 1990;15:41-8.
  35. Pizzo PA.  Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
  36. Ramphal R, Bolger M, Oblon DJ, et al.  Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992;36:1062-7.
  37. Rolston KVI.  Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia.  Clin Infect Dis 2005;40(suppl 4):S246-52.
  38. Rotstein C, Bow EJ, et al.  Adult patient care plan:  management of the febrile neutropenic cancer patient on an outpatient basis.  Can J Infect Dis 2000;11(suppl D):27D-33D.
  39. Rozdzinski E, Kern WV, Reichle A, et al.  Once-daily versus thrice-daily dosing of netilmicin in combination with b-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31:585-98.
  40. Sanders JW, Powe NR, Moore RD.  Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 1991;164:907-16.
  41. Zinner SH.  Changing epidemiology of infections in patients with neutropenia and cancer:  emphasis on gram-positive and resistant bacteria.  Clin Infect Dis 1999;29:490-4.
Content Version: 1.1.1151 Oct 31, 2024.06:09
©1998-2020 Alberta Health Services